Scholarlink

Introduction <p>Monitoring patient-reported symptoms over time may support early detection of medicine-related harms. The Pharmacotherapeutic Symptom Evaluation-20–Australian version (PHASE-20–Australian version) is an 11-point rating scale designed for longitudinal monitoring of medicine-related symptoms; however, its responsiveness and minimum important change (MIC) have not been established.</p> Aim <p>To evaluate the responsiveness and MIC of the PHASE-20–Australian version for monitoring changes in medicine-related symptoms over time.</p> Method <p>A prospective cohort study was conducted among Australian adults (≥ 18&#xa0;years) taking medications. Participants completed the PHASE-20–Australian version at baseline and follow-up and reported perceived symptom changes using the Global Rating Scale (GRS) at follow-up. Responsiveness was assessed by correlating score changes with the GRS and calculating the area under the receiver operating characteristic (ROC) curve (AUC). MIC was estimated using ROC anchor-based and 0.5 standard deviation (SD) distribution-based methods and then compared with the Smallest Detectable Change (SDC).</p> Results <p>Among 102 participants, 52% were aged ≥ 60&#xa0;years and 65.7% were female. Strong correlations were observed for overall score changes (<i>rho</i> = 0.815) with the GRS as well as for 84.2% of individual symptoms (<i>rho</i> = 0.701–0.897). The tool demonstrated good to strong discriminative ability (AUC = 0.739–0.975 for improvement; 0.764–0.977 for deterioration), with sensitivity and specificity ≥ 0.75 for 16 symptoms. The MIC values ranged from 0.5 to 1.5 using the ROC method and 0.9–1.8 using the 0.5 SD approach. The estimated MIC values exceeded the SDC for 84.2% of symptoms. Limited responsiveness (<i>rho</i> &lt; 0.7, AUC &lt; 0.7) and MIC values below the SDC were noted for forgetful, swollen legs/ankles and frequent urination/incontinent of urine.</p> Conclusion <p>The PHASE-20–Australian version is responsive for most symptoms, with a clinically meaningful change of approximately 2.0 points on a 0–10 scale. The estimated MIC is applicable at the individual level, although caution is needed for symptoms with an MIC below the SDC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Responsiveness and minimum important change of the Pharmacotherapeutic Symptom Evaluation-20–Australian version: a tool for measuring changes in medicine-related symptoms over time

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月12日

查看全文
  • Abebe Basazn Mekuria,
  • Andre Q. Andrade,
  • Renly Lim,
  • Debra Rowett,
  • Mariann Hedström,
  • Elizabeth E. Roughead

摘要

Introduction

Monitoring patient-reported symptoms over time may support early detection of medicine-related harms. The Pharmacotherapeutic Symptom Evaluation-20–Australian version (PHASE-20–Australian version) is an 11-point rating scale designed for longitudinal monitoring of medicine-related symptoms; however, its responsiveness and minimum important change (MIC) have not been established.

Aim

To evaluate the responsiveness and MIC of the PHASE-20–Australian version for monitoring changes in medicine-related symptoms over time.

Method

A prospective cohort study was conducted among Australian adults (≥ 18 years) taking medications. Participants completed the PHASE-20–Australian version at baseline and follow-up and reported perceived symptom changes using the Global Rating Scale (GRS) at follow-up. Responsiveness was assessed by correlating score changes with the GRS and calculating the area under the receiver operating characteristic (ROC) curve (AUC). MIC was estimated using ROC anchor-based and 0.5 standard deviation (SD) distribution-based methods and then compared with the Smallest Detectable Change (SDC).

Results

Among 102 participants, 52% were aged ≥ 60 years and 65.7% were female. Strong correlations were observed for overall score changes (rho = 0.815) with the GRS as well as for 84.2% of individual symptoms (rho = 0.701–0.897). The tool demonstrated good to strong discriminative ability (AUC = 0.739–0.975 for improvement; 0.764–0.977 for deterioration), with sensitivity and specificity ≥ 0.75 for 16 symptoms. The MIC values ranged from 0.5 to 1.5 using the ROC method and 0.9–1.8 using the 0.5 SD approach. The estimated MIC values exceeded the SDC for 84.2% of symptoms. Limited responsiveness (rho < 0.7, AUC < 0.7) and MIC values below the SDC were noted for forgetful, swollen legs/ankles and frequent urination/incontinent of urine.

Conclusion

The PHASE-20–Australian version is responsive for most symptoms, with a clinically meaningful change of approximately 2.0 points on a 0–10 scale. The estimated MIC is applicable at the individual level, although caution is needed for symptoms with an MIC below the SDC.